Figure 7. T‐025 exerted anti‐tumor activity in MYC‐driven breast cancers.

• A, B
  Anti‐tumor efficacy of T‐025 in a MMTV‐MYC allograft model. T‐025 was administered twice daily on 2 days per week (red arrow). Tumor volume (A) and body weight (B) during the treatment cycle are shown. Data are shown as means ± standard errors of the means (n = 8).
• C
  Kaplan–Meier survival curve of breast cancer patients categorized as an ER‐positive, HER2 negative, and high‐proliferative subpopulation. Patients were divided into two groups by MYC‐amplified status and expression level of CLK2. Median survival time of each group was calculated by Prism, and a log rank test was performed.

Data information: In (A and B), an unpaired Student's t‐test or an unpaired Student's t‐test with Welch's correction was performed.